Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 8/20 | 0.58 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.58 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15137456 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL3885456 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL8429329 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL1668605 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL9232535 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL1666797 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL1666654 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL3171119 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL9235193 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL11359586 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9110058-B2 | Porous solid phase for binding assay, and binding assay method using the same | SEKISUI MEDICAL CO., LTD. (JP) | 2015-08-18 | — | — | US | claimed |
| US-20230151442-A1 | RAPID DETECTION OF VIRAL INFECTION USING RT-PCR | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-18 | — | — | US | disclosed |
| EP-4133101-A1 | RAPID DETECTION OF VIRAL INFECTION USING RT-PCR | Bayer Aktiengesellschaft (DE) | 2023-02-15 | — | — | EP | disclosed |
| US-20070015185-A1 | Lysis and stabilization buffer suitable for inclusion in PCR reactions | STRATAGENE | 2007-01-18 | — | — | US | disclosed |
| WO-2006138444-A2 | LYSIS AND STABILIZATION BUFFER SUITABLE FOR INCLUSION IN PCR REACTIONS | STRATAGENE (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060286557-A1 | Combined lysis and PCR buffer | STRATAGENE | 2006-12-21 | — | — | US | disclosed |
| US-6660494-B2 | Detecting phosphatidylcholine-specific phospholipase-C enzyme via incorporation of 3-indoxyl choline phosphate into substrate | BIOSYNTH AG (CH) | 2003-12-09 | — | — | US | disclosed |
| US-20030204077-A1 | RNA isolation reagent and methods | INVITROGEN CORPORATION | 2003-10-30 | — | — | US | disclosed |
| EP-1219628-B1 | Novel substrates for detection of microbial metabolites | BIOSYNTH AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| WO-2003023062-A2 | METHOD OF DIAGNOSIS FOR C.TRACHOMATIS INFECTION USING DNA AMPLIFICATION ASSAY ON LIQUID CYTOLOGY SAMPLES | SONIC CLINICAL INSTITUTE PTY LIMITED (AU) | 2003-03-20 | — | — | WO | disclosed |
| EP-1005479-A4 | RNA ISOLATION REAGENT AND METHODS | LIFE TECHNOLOGIES INC (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020151725-A1 | Detection of microbial metabolites | BIOYNTH AG (CH) | 2002-10-17 | — | — | US | disclosed |
| WO-2002051853-A1 | DETECTION OF MICROBIAL METABOLITES | BIOSYNTH AG (CH) | 2002-07-04 | — | — | WO | disclosed |
| EP-1219628-A1 | Novel substrates for detection of microbial metabolites | Biosynth AG (CH) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001061029-A2 | IDENTIFICATION METHOD | ZETATRONICS LIMITED (GB) | 2001-08-23 | — | — | WO | disclosed |
| WO-2000058503-A2 | IMPROVED METHOD FOR DETECTING MICRO-ORGANISMS | ZETATRONICS LIMITED (GB) | 2000-10-05 | — | — | WO | disclosed |
| EP-1005479-A1 | RNA ISOLATION REAGENT AND METHODS | LIFE TECHNOLOGIES, INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| EP-0953357-A1 | NEPHROTROPIC DRUGS | Drug Delivery System Institute, Ltd. (JP) | 1999-11-03 | — | — | EP | disclosed |
| WO-1998045311-A1 | RNA ISOLATION REAGENT AND METHODS | LIFE TECHNOLOGIES, INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204077-A1 | RNA isolation reagent and methods | RNASE1, RNASEH1, RNGTT | LGALS3 719/4885LGALS1 1386/4885LGALS9 1592/4885 |
| US-20070015185-A1 | Lysis and stabilization buffer suitable for inclusion in PCR reactions | POLL, TCEA1, CTSE | LGALS3 2131/4885LGALS1 1512/4885LGALS9 1425/4885 |
| US-20020151725-A1 | Detection of microbial metabolites | LCT, CEL, PLCB1 | LGALS3 1509/4885LGALS1 1080/4885LGALS9 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.